Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril–Valsartan in Clinical Trials : American Journal of Therapeutics

Secondary Logo

Journal Logo

Letters to the Editor

Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril–Valsartan in Clinical Trials

Cordero, Alberto MD, PhD, FESC1,2; Nuñez, Julio MD, PhD, FESC2,3; Bertomeu-González, Vicente MD, PhD, FESC1,2; Fácila, Lorenzo MD, PhD4; Quintanilla, Mª Amparo MD, PhD1; Rodríguez-Mañero, Moisés MD, PhD2,5; Escribano, David MD1; Valle, Alfonso MD, PhD6; de la Espriella, Rafael MD, PhD2,3; Torres-Llergo, Javier MD7; Bayés-Genís, Antoni MD, PhD, FESC2,8; González-Juanatey, José R. MD, PhD, FESC, FACC2,5

Author Information
American Journal of Therapeutics 29(5):p e572-e575, September/October 2022. | DOI: 10.1097/MJT.0000000000001503
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid